- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04583657
Intestinal Tolerance & Health Effects of Daily Consumption of Two Eggs With Fatty Acid Profile Related to Metabolic Disorders (Oil4Egg)
To Evaluate the Intestinal Tolerance and Health Effects of Daily Consumption of Two Eggs With a Particular Fatty Acid Profile on a Set of Parameters Related to Metabolic Disorders
This study has two objectives: 1) to check that the daily consumption of two eggs with a particular fatty acid pattern rich in n-3 polyunsaturated fatty acids (α-linolenic acid, docosahexaenoic acid), conjugated-linoleic acid and conjugated-linolenic acid is well tolerated by the consumer ; 2) to evaluate the effects of the consumption of these eggs on health parameters in subjects presenting a risk of developing a metabolic disorder.
This monocentric study is an interventional, randomized, double-blind, control study.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids show interesting effects in the context of health. Indeed, some studies suggest positive effects on circulating lipids or inflammation associated with certain disorders such as diabetes, following the consumption of these fatty acids.
However, these fatty acids are not very present in the classic diet. Therefore, we have developped hens eggs naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids by changing the hens feed.
This study has two objectives: 1) to check that the daily consumption of two eggs with a particular fatty acid pattern rich in n-3 polyunsaturated fatty acids (α-linolenic acid, docosahexaenoic acid), conjugated-linoleic acid and conjugated-linolenic acid is well tolerated by the consumer ; 2) to evaluate the effects of the consumption of these eggs on health parameters in subjects presenting a risk of developing a metabolic disorder.
To do this, 80 subjects aged 35 to 75, sedentary (<2 hours of physical activity per week) and with abdominal obesity (> 94cm for men and> 80cm for women) were recruited and were divided into two groups: the control group (12 subjects consuming 2 classic eggs for 3 months per day) or the test group (12 subjects consuming 2 eggs enriched in omega per day for 3 months).
A medical examination with blood sampling was scheduled every month at baseline (Day 0), after one month (Day 30), after two months (Day 60) and at the end of the 3 months of intervention (Day90). During those visits, the following were monitored: glucose parameters, lipids parameters, fatty acid profile of red blood cells and plasma and safety parameters related to haematology, kidney and liver functions .
During these monthly medical visits patients also completed the questionnaires assessing intestinal tolerance (visual analogue scale showing 10 gastrointestinal symptoms), satiety (visual analog scale questionnaire) and well-being (36 items short form survey). Eating habits were monitored using a food diary. Additional parameters were measured only during the first and the last visit: coagulation, nutritional status, endothelial function and inflammation.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Louvain-La-Neuve, Belgien, 1348
- Center of Investigation in Clinical Nutrition
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Woman or man, aged of 35 to 75 years
- Abdominal obesity : waist circumference for men > 94cm and > 80cm for women
- Practicing < 2h of physical activity per week
Exclusion Criteria:
- Uncontrolled systolic blood pressure > 160/100mmHg
- For premenopausal women: pregnant or lactating women
- For menopausal women: less than 6 months of menopause
- Perimenopausal women with symptoms
- Type II diabetes (fasted glycaemia ≥ 126mg/dl or HbA1c ≥ 6.5%), Type I diabetes
- Medical history or actual cardiovascular disease (myocardial infarction, angina, transient ischemic attack, lower limb arteriopathy)
- Familial history of premature cardiovascular incident (in male first degree relative < 55 years and in female first degree relative < 65 years; myocardial infarction, angina, transient ischemic attack, lower limb arteriopathy)
- Medical history or actual liver, pancreas, kidney, pulmonary or gastrointestinal problem
- Thyroid disorder
- Cancer < 5 years before the screening visit
- Smokers or who have stopped smoking within 6 months before the screening visit
- Subject presenting allergy or food intolerance to eggs
- Subjects with psychiatric problems and/or using antipsychotics
- Drug addiction problem
- Recent change of body weight > 5kg (< 3 months before the screening visit)
Within 3 months before the screening visit, change in the chronic (> 7 days in a row) intake or dosage of drug(s) or product(s) modifying
- The glucose or lipid metabolism
- The blood pressure and heart rate
- Intestinal tolerance
- Hepatic, pancreas or kidney functions
- Satiety
- The inflammatory status
- Current or recent (< 3 months before the screening visit) intake of dietary supplements rich in n-3 polyunsaturated fatty acid
- Vegan diet
- Consumption of fish > 3 times per week
- Subjects who drink more than 3 glasses of alcohol per day (> 30 g of alcohol per day)
- LDL > 159 mg/dl or total cholesterol > 239 mg/dl or triglyceride > 200 mg/dl or HDL < 40 mg/dl
- Docosahexaenoic acid in red blood cell phospholipids > 8 %
- Subjects having participated to another clinical trial < 1 month before the screening test visit
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Control
Consumption of two "classical eggs" per day during three months.
The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%.
|
Consumption of two eggs (control or test) per day during three months
|
|
Experimental: Test
Consumption of two test eggs per day during three months.
These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%,
total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)
|
Consumption of two eggs (control or test) per day during three months
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Glycated haemoglobin (HbA1c)
Zeitfenster: Change from baseline (visit 1) glycated haemoglobin at 3 months (Day 90, visit 4)
|
Glycated haemoglobin (HbA1c) in blood samples
|
Change from baseline (visit 1) glycated haemoglobin at 3 months (Day 90, visit 4)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Glucose
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Insulin
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Homeostatic model assessment (HOMA)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Quantitative insulin sensitivity check index (QUICKI)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Triglycerides
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Total cholesterol
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
low-density lipoprotein (LDL) cholesterol
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
high-density lipoprotein (HDL) cholesterol
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
non-high-density lipoprotein cholesterol (non-HDL)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fatty acid pattern in red blood cells
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fatty acid pattern plasma
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Urea
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Uric acid
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Creatinine
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Glomerular filtration rate (GFR)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Sodium (Na)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Potassium (K)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Chlore (Cl)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Phosphate (P)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Alanine transaminase (ALAT)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Aspartate aminotransferase (ASAT)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Gamma-glutamyl transferase (GGT)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Alkaline phosphatase (ALP)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Lipase
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Haemoglobin
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Mean corpuscular volume (MCV)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Mean corpuscular hemoglobin concentration (MCHC)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Red blood cells
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
White blood cells
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Blood cell count
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Reticulocytes
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Haematocrit
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Body weight
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Waist circumference
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Measuring tape
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Hip circumference
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Measuring tape
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fat mass
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Lean mass
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Visceral fat mass
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
International normalized ratio (INR)
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Activated clotting time (ACT)
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Iron
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Transferrin
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Ferritin
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
% transferrin saturation
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Vitamin B12
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
25-hydroxy-vitamin D
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Protein
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Albumin
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
C-reactive protein (CRP)
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Interleukin-6
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Interleukin-1b
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Tumor necrosis factor alpha (TNFa)
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Oxidized low-density lipoprotein (LDLox)
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Nitrosylated hemoglobin (HbNO)
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Satiety
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
visual analog scale questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Intestinal tolerance
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
visual analog scale questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Quality of life 36-item short-form survey (SF36)
Zeitfenster: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
SF36 questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Reactive hyperemia index (LnRHI)
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
Tonometry
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Augmentation index normalized for heart rate (AI@75bpm)
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
Tonometry
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Systolic blood pressure
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
Tensiometer
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Diastolic blood pressure
Zeitfenster: baseline (visit 1) and Day 90 (last visit 4)
|
Tensiometer
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Glycated haemoglobin (HbA1c)
Zeitfenster: Day 30 (visit 2) and Day 60 (visit 3)
|
Glycated haemoglobin in blood sample
|
Day 30 (visit 2) and Day 60 (visit 3)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Yvan Larondelle, Prof, Université Catholique de Louvain
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Oil4Egg
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .